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A B S T R A C T
Haemonchus contortus, one of the most economically important parasites of small ruminants, has become re-
sistant to the anthelmintic ivermectin. Deciphering the role of P-glycoproteins in ivermectin resistance is de-
sirable for understanding and overcoming this resistance. In the model nematode, Caenorhabditis elegans, P-
glycoprotein-13 is expressed in the amphids, important neuronal structures for ivermectin activity. We have
focused on its ortholog in the parasite, Hco-Pgp-13. A 3D model of Hco-Pgp-13, presenting an open inward-
facing conformation, has been constructed by homology with the Cel-Pgp-1 crystal structure. In silico docking
calculations predicted high affinity binding of ivermectin and actinomycin D to the inner chamber of the protein.
Following in vitro expression, we showed that ivermectin and actinomycin D modulated Hco-Pgp-13 ATPase
activity with high affinity. Finally, we found in vivo Hco-Pgp-13 localization in epithelial, pharyngeal and
neuronal tissues. Taken together, these data suggest a role for Hco-Pgp-13 in ivermectin transport, which could
contribute to anthelmintic resistance.
1. Introduction
Parasite nematodes cause morbidity in animals and humans and
macrocyclic lactones (ML), such as ivermectin (IVM), are important
anthelmintic drugs for therapy (Campbell, 2016; Omura, 2016). How-
ever, the long-term use of ML has led to the development of drug re-
sistance, challenging therapeutic control (Kaplan and Vidyashankar,
2012).
The multi-drug resistance (MDR) transporters from the ATP-binding
cassette (ABC) protein superfamily are involved in the transport of
structurally unrelated xenotoxins, and have been recognized as major
players in resistance to drugs in mammals, bacteria and parasites (Lage,
2003; Jones and George, 2005; Koenderink et al., 2010). In mammals,
P-glycoprotein (MDR1/ABCB1/Pgp) can efflux structurally unrelated
drugs, including IVM (Schinkel et al., 1994; Pouliot et al., 1997; Roulet
et al., 2003; Lespine et al., 2007). Many Pgps, i.e. full-size transporters
of the B sub-family, are expressed in nematodes, and they display fair
sequence homologies with human ABCB1. The free-living nematode
Caenorhabditis elegans expresses sixty ABC proteins, among which
fourteen Pgp homologs are localized in different organs and expressed
at various stages of development (Zhao et al., 2004). Haemonchus con-
tortus, one of the most prevalent pathogen parasitic nematodes in small
ruminants, is genetically close to Caenorhabditis elegans and its genome
has recently been sequenced (Laing et al., 2013) (ftp://ftp.sanger.-
ac.uk/pub/pathogens/Haemonchus/contortus). In this species, ten
homologs of Pgps were identified, and two have been localized: Hco-
Pgp-2 in the pharynx, anterior intestine and head neurons, and Hco-
Pgp-9.1 in the uterus of females (Godoy et al., 2015a, 2016).
There is indirect but converging evidence that some nematode Pgps
can transport ML, in C. elegans (Ardelli and Prichard, 2013; Janssen
et al., 2013a, 2015) and in Parascaris equorum (Janssen et al., 2013b).
Some mammalian Pgp inhibitors alter the transport function of Pgps in
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C. elegans and in the parasitic nematodes H. contortus, Cylicocylus
elongatus and Dirofilaria immitis (Kaschny et al., 2015; Godoy et al.,
2015a, 2015b, 2016; Mani et al., 2016). Such inhibitors can also im-
prove the susceptibility of nematodes to ML (Bartley et al., 2009; James
and Davey, 2009; Lespine et al., 2012; Menez et al., 2016). In addition,
increased ML resistance is associated with induction of expression of
Pgp genes (James and Davey 2009; Lespine et al., 2012). Recently,
using the first crystal structure of a nematode Pgp, Cel-Pgp-1, resolved
at a resolution of 3.4 Å (Protein Data Bank code: 4F4C) (Jin et al.,
2012), high affinity binding of several anthelmintic drugs, including
IVM, on Cel-Pgp-1 has been predicted by in silico docking calculations
(David et al., 2016).
To understand the respective physiological functions of Pgps in H.
contortus, it is of interest to consider their sites of expression. In both C.
elegans and H. contortus, IVM resistance has been linked to defects in the
morphology of the amphids (Freeman et al., 2003; Urdaneta-Marquez
et al., 2014; Menez et al., 2016). Cel-Pgp-6 and Cel-Pgp-13 are expressed
in the amphids (Zhao et al., 2004). H. contortus does not have a
homolog of Cel-Pgp-6, but it has a homolog of Cel-Pgp-13, and it was
therefore of interest to characterize Hco-Pgp-13. Full-length Hco-Pgp-13
cDNA was cloned and transfected into Pichia pastoris which stably ex-
pressed functional Hco-Pgp-13. Based on the crystal structure 4F4C of
Cel-Pgp-1 (Jin et al., 2012), the protein was 3D modeled in open in-
ward-facing conformation, which is expected to be competent for sub-
strate uptake, leading to two high-quality, alternative but com-
plementary, structural models. Using in silico docking on these models,
in combination with in vitro ATPase assays on membranes of Hco-Pgp-13
transfected P. pastoris, we show for the first time that actinomycin D
(ACD) and IVM specifically bind to Hco-Pgp-13 and modulate its AT-
Pase activity, and could hence be transported by the parasitic Hco-Pgp-
13. Furthermore, the expression of Hco-Pgp-13 in the tissues of H.
contortus larvae and adults was assessed. Our finding of apparent Hco-
Pgp-13 expression in digestive, epithelial and neuronal tissues is con-
sistent with a general detoxification function, possibly handling various
xenobiotics, in analogy with ABCB1 in mammals. Finally, in the context
of anthelmintic drug resistance in parasitic nematodes, Hco-Pgp13 is
likely to have a role in IVM resistance.
2. Material and methods
2.1. Parasites
The PF23 strain of H. contortus used is susceptible to MLs (Ranjan
et al., 2002). Worms were originally supplied by Fort Dodge Animal
Health, Princeton, NJ, USA and were maintained by our laboratory.
Animals and standardized operating procedures used in this research
study were approved (Protocol 3845) and subjected to the guidelines
from the Animal Care Committee of McGill University, Canada. Worms
were obtained from passages consisting of an artificial infection with
the larvae from the previous generation in naive lambs, without an-
thelmintic exposure. They were then collected from the abomasum of
the host and incubated in PBS at 37 °C before storage at -80 °C.
2.2. RNA extraction and reverse transcription
Total RNA was extracted from twenty adult H. contortus, homo-
genized and extracted according to the instruction of the manufacturer
(ThermoFisher, Canada). RNA concentration was determined with a
Nanodrop photometer IMPLEN® at a wavelength of 260 nm and as-
sessed by gel electrophoresis. Good quality RNA was stored at -80 °C.
The reverse transcription to cDNA was performed using the
SuperScript® III reverse transcriptase (ThermoFisher, Canada), starting
with 1 μg RNA and following the instructions of the manufacturer. The
cDNA obtained was stored at -20 °C for further use.
2.3. Amplification of the Hco-Pgp-13 cDNA sequence
A pair of primers, Hco-Pgp-13-F1 and Hco-Pgp-13-R2 (Suppl. Table
S1), were designed using the Geneious software version 5.5.6. (http://
www.geneious.com/; PO Box 5677, Wellesley St, Auckland 1141, New
Zealand), across the 3’ end of the predicted sequence of Hco-Pgp-13
from the Sanger Institute (ftp://ftp.sanger.ac.uk/pub/pathogens/Hae-
monchus/contortus) (Laing et al., 2013). A first PCR was run using
these primers and the reverse transcribed cDNA of whole adult H.
contortus as template. A fragment of 3488bp was obtained and se-
quenced (Genome Quebec Innovation Centre, McGill University, QC,
Canada) using eight primers, Hco-Pgp-13-F1 to Hco-Pgp-13-R8
(Supplementary Table S1).
Four more primers were designed to identify the 5′-end of Hco-Pgp-
13 by nested PCR: the nematode spliced leader sequence SL1 (Blaxter
and Liu, 1996), a specific forward primer Hco-Pgp-13–F9
(Supplementary Table S1) and two specific reverse primers Hco-Pgp-
13–R10 and Hco-Pgp-13-R11 (Supplementary Table S1). The 887 bp
PCR products thus obtained were sequenced and aligned to the first
3488 bp product with MultAlin software (Corpet, 1988), and the
overlap of the amplicons confirmed. The full-length sequence was then
aligned against the cDNA of the predicted sequence of Hco-Pgp-13 using
MultAlin (Supplementary Figure S1).
2.4. Determination of Hco-Pgp-13 protein sequence, phylogenic analysis
and calculation of TMD homologies relative to Cel-Pgp-1
The translation of Hco-Pgp-13 cDNA into protein sequence was
performed using ExPASy – Translate tool (http://web.expasy.org/
translate/). The parameters of the protein (molecular weight, length)
were calculated with ExPASy – ProtParam (http://web.expasy.org./
protparam/). The presence of N- and O-glycosylation motifs was pre-
dicted using ExPASy - ScanProsite tool (http://prosite. Expasy. org/), as
well as that of consensus motifs, including the Walker A and the less
conserved Walker B motif. Multiple sequence alignment of Pgps of
various organisms, including Hsa-Pgp (Supplementary Figure S2), was
performed using Muscle algorithm under Seaview software (Edgar,
2004a, 2004b). The prediction of amino acids located within the
transmembrane bilayer was performed with the Protter tool (Omasits
et al., 2014) and the TMHMM Server v. 2.0 (http://www.cbs.dtu.dk/
services/TMHMM/). The visualization of the topology of the full length
protein sequence across the plasma membrane was represented using
the Protter tool (Fig. 1). The TM helices and eight N-glycosylation
motifs were represented as predicted by this program, N518 being the
only one not previously predicted by ExPASy - ScanProsite.
A PhyML phylogenetic tree with all Hco-Pgps, all Cel-Pgps, Hsa-Pgp
and Mmu-ABCB1a protein sequences (Fig. 2) was constructed using
Seaview software from the multiple alignments previously performed
with Muscle (Supplementary Figure S2) after removal of NBDs from all
the considered protein sequences.
The locations of the TMDs of all the proteins of this alignment were
deduced from Cel-Pgp-1 4F4C crystal structure (Jin et al., 2012). The
first amino acid of TMD1 of each Pgp was identified as the one aligned
to the first amino-acid of TM1 of Cel-Pgp-1, thus excluding the small
extra-helix TMa and TMb (Jin et al., 2012) not previously described in
other ABC transporters, and considered to be part of the N-terminal
region. The similarity and identity percentages of the TMDs of Cel-Pgp-
1 with the TMDs of all other Pgps were then determined using BlastP
(http://blast.ncbi.nlm. nih. gov/Blast.cgi). TMD1 and TMD2 were
considered independently, and the mean of the two values for each Pgp
is reported in Table 1.
2.5. Design of specific antibodies against Hco-Pgp-13
The specificity and suitability of various antigens for antibody
production against Hco-Pgp-13 were analyzed by GenScript. Among
M. David et al. IJP: Drugs and Drug Resistance 8 (2018) 145–157
146
several potential antigenic determinants identified, two peptides were
chosen for their disordered structure and high accessibility in the pre-
dicted 3D conformation of the protein: GTADPQRSSETSKK (residues
12-25) and SGRSTLTQSKRSGS (residues 681-694). They were chemi-
cally synthesized and used to immunize rabbits (GenScript, USA). The
polyclonal antibodies generated were assessed in Western blots.
2.6. Expression of Hco-Pgp-13
The full-length cDNA sequence of Hco-Pgp-13 was subjected to
codon optimization by GenScript (NJ, USA). After transformation of the
vector in Escherichia coli TOP10F’ competent cells, Hco-Pgp-13 codon
optimized sequence was confirmed by sequencing (Genome Quebec
Innovation Centre, McGill University, QC, Canada). Expression of
codon optimized Hco-Pgp-13 was undertaken in both epithelial pig
kidney cells (LLC-PK1) and P. pastoris. Membrane fractions extracted
from Hco-Pgp-2/LLC-PK1 transfected cells (Godoy et al., 2015a) and
from Hco-Pgp-13/LLC-PK1 were prepared as previously described
(Garrigues et al., 2002).
For expression in P. pastoris, Hco-Pgp-13 coding sequence was
modified at the 5′ end and the 3′ end by introducing BstBI and XbaI
sites, respectively, by PCR amplification with the following primers:
BstBI-Hco-Pgp-13: 5′AAAACAACTTAATTATTATTCGAAACGATGACAT
CAAAACCCGAT′3 (forward) and XbaI-Hco-Pgp-13: 5′TAGCTAGCTAGC
TAGCTAGTGTTCTAGAGGCCCTGTGGTGAGG TCCTGC′3 (reverse).
Modified PCR cDNA was digested using BstBI and XbaI enzymes and
cloned in the pPICZ-HuMOR-cmyc-his-tag vector (Sarramegna et al.,
2005) digested with the same enzymes leading to the creation of pPICZ-
Hco-Pgp-13-cmyc-his-tag vector.
E. coli strain Top10F’ was used for the propagation of recombinant
plasmids. E. coli transformants were selected on low salt LB plates pH
7.5 (0.5% w/v yeast extract, 1% w/v tryptone, 0.5% w/v NaCl, 1.5%
w/v bacteriological agar) supplemented with 25 μg zeocin/ml. P. pas-
toris SMD1163 (his4, pep4, prB1) strain was used for protein expres-
sion. Transformants were selected on YPDS plates (1% w/v yeast ex-
tract, 2% w/v peptone, 2% w/v dextrose, 1M sorbitol, and 1.5% w/v
bacteriological agar) with 100 μg zeocin/ml. P. pastoris growth and
induction were performed in BMGY medium (1% w/v yeast extract, 2%
w/v peptone, 0.1 M phosphate buffer pH 7.5, 1% v/v glycerol) and
BMMY medium (same as BMGY except that glycerol was replaced by
0.5% v/v methanol), respectively. For some experiments growth and
recombinant protein expression were undertaken at the same time in
BMMY medium. Cell cultures were conducted at 30 °C in shacking
flasks.
2.7. Cell membrane preparation and western blot
P. pastoris and LLC-PK1 cells were harvested and ruptured during
Fig. 1. Primary sequence (A) and predicted topology (B) of Hco-Pgp-13. The amino acid sequence was predicted using ExPASy - Translate, the various motifs were found using
ExPASy – ScanProsite, and the topology was represented with Protter. The sequence of transmembrane domains (TMDs), TMD1 (residues 95-383) and TMD2 (residues 756-1043), and
nucleotide binding domains (NBDs), NBD1 (residues 418-654) and NBD2 (residues 1076-1312), are colored in red and blue characters, respectively (A), or as cellular topology in red and
blue circles, respectively (B). Within each NBD, the Walker A domain sequence is highlighted in light blue and the Walker B motif in dark blue (A and B), in squares (B). The tyrosine
residue forming the A-loop of each domain is highlighted in black (A and B), and the C-loop/ABC transporter signature motif is highlighted in grey (A and B); both are circled in (B).
Putative N-glycosylation motifs (Asn 191, 507, 518, 601, 704, 747, 984 and 1033) are highlighted in dark green (A and B), in squares (B). Protein regions chosen as antigenic determinant
n°1 (N-term region) and n°2 (between NBD1 and TMD2) are both highlighted in light green (A), in diamonds (B). The ten residues sequence within the black box (A) was duplicated in the
predicted sequence published by Laing et al. (2013) (See Supplementary Fig. S1). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web
version of this article.)
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30min with glass beads, or by sonication, in buffer (Tris/HCl 10mM,
pH 7.5) supplemented with protease inhibitors, at 4 °C. The cell lysate
was centrifuged at 1,000g for 15min to remove particulate matter. The
supernatant was then centrifuged at 100,000g for 30min. Resulting
pellets were stored at -80 °C in the same buffer. Membrane protein
content was determined using the Bradford assay (Bio-Rad), using bo-
vine serum albumin (BSA) as standard.
SDS-PAGE and transfer to nitrocellulose were performed as de-
scribed (Gallagher, 2016). The primary anti-His tag antibody (Thermo
Scientific) was diluted 1:1000 as well as the two primary antibodies
designed against each epitope of Hco-Pgp-13. The secondary CF™770
anti-rabbit antibody (Biotium, Fremont, CA, USA) was used at a
1:10000 dilution. Detection was carried out using the Odyssey® CLx
imaging system (LI-COR Biosciences, Lincoln, NE, USA).
2.8. ATPase activity measurements
The vanadate-sensitive ATPase activity of freshly prepared crude
membranes from P. pastoris cells transformed by pPICZ-Hco-Pgp-13-
cmyc-his-tag vector (Hco-Pgp-13: three membrane preparations) were
compared to P. pastoris cells transformed by pPICZ-HuMOR-cmyc-his-
tag vector (Sarramegna et al., 2005) (Hu-MOR: two membrane pre-
parations) as negative controls and to untransfected P. pastoris cells
(WT: three membrane preparations). The ATPase activity was measured
at 37 °C by the endpoint inorganic phosphate (Pi) release assay (Sarkadi
et al., 1992). Briefly, membrane preparations (200 μg/ml) were pre-
incubated at 37 °C in ATPase assay buffer (50mM HEPES (pH 7.5),
10mM MgCl2, 1 mM dithiothreitol, 0.1 mM EGTA, 10 mM sodium
azide, 1 mM ouabain) in the presence or absence of 100 μM sodium
orthovanadate and with increasing concentrations of either ACD or
IVM. DMSO (final concentration was 1%) was used as solvent for the
drugs and in the control measurements. The reaction was initiated by
the addition of 5 mM ATP and stopped with 5% SDS solution after 5, 15
and 30 min of incubation. The amount of Pi released was determined at
each time point in triplicate and the mean initial hydrolysis rate was
calculated in nmol Pi/min/mg of total membrane protein (+/- SD). The
vanadate sensitive activity values were estimated as the difference be-
tween the rate in the presence and absence of vanadate. For studying
ACD-induced ATPase, in each of the different membrane preparations,
data were normalized to 100% with respect to the vanadate-sensitive
activity measured in the absence of added drug. For studying IVM
modulation of ATPase activity data are presented as absolute values. In
order to quantitatively analyze the interaction of ACD and IVM with
Hco-Pgp-13, we assumed that these ligands have one specific site (or
indepemdent sites) on the protein, and fitting was carried out using
non-linear regression with GraphPad PRISM.
Fig. 2. Maximum likelihood phylogenetic tree of mammalian and nematode Pgp protein sequences. A PhyML phylogenetic tree of a set of sequences comprising Hco-Pgps, Cel-
Pgps, Hsa-ABCB1 and Mmu-ABCB1a protein sequences, with their NBD regions removed, was built using Seaview software, based on the Muscle alignment shown in Supplementary
Figure S2. The bar represents the relative scale of distance, expressed in number of substitutions per site of the sequence alignment.
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2.9. Construction of 3D models of Hco-Pgp-13 and in silico docking
calculations
All Modeller and Autodock calculations were performed using the
computing facilities of the CEA-DSV/GIPSI (cluster Gabriel) at Saclay,
France and of INRA (Genotoul) in Toulouse, France. 3D models of Hco-
Pgp-13 were built using Modeller 9v12 (Sali and Blundell, 1993; Webb
and Sali, 2014) based on the crystal structure of C. elegans Pgp-1 (PDB:
4F4C, determined at a resolution of 3.4 Å), as a template (Jin et al.,
2012). As the Cel-Pgp-1 sequence was lacking the following amino
acids: M1-R3, A52-E54, K666-E715 and G1307-K1321, the full-length
sequence of Hco-Pgp-13 was modeled without the corresponding
aligned residues: M1-S3, E668-L725, and G1304-T1317. The pairwise
alignment was deduced from the multiple alignment (Supplementary
Figure S2) in order to improve the accuracy of the homology modeling
alignment used as input for Modeller 9v12. Then, 100 models were
generated in each Modeller run, and they were ranked according to
their DOPE (Discrete Optimized Protein Energy) score and their mole-
cular PDF value of the optimized objective function of Modeller. The
best DOPE score model, n°4 (Hco-Pgp-13_04), and the best molecular
PDF model, n°52 (Hco-Pgp-13_52), were submitted to various online
servers to assess their protein structure quality (Supplementary Table
S2). The QMEAN (Qualitative Model Energy Analysis) scoring function
(Benkert et al., 2008, 2009), the ProSA-web (Protein structure analysis)
(Sippl, 1993; Wiederstein and Sippl, 2007) and the VADAR (Volume,
Area, Dihedral Angle Reporter) (Willard et al., 2003) servers all in-
dicated very close assessment for the two models according to different
parameters, so that both of them were retained for docking calculations.
The in silico docking calculations for ACD and IVM on Hco-Pgp-13
were performed as previously described (David et al., 2016). The
structure of ACD was extracted from DrugBank n° DB00970 and the
structure of IVM was extracted from the Merck Index (https://www.rsc.
org:merck-index). For both molecules, 10 minimum energy conformers
were generated with Marvin Suite under the MMFF94 force field
(https://www.chemaxon.com/products/marvin/marvinsketch/). After
3D-alignment and calculation of RMSD under PyMOL four re-
presentative conformers were chosen for starting the docking calcula-
tions. Molecular docking experiments were performed using AutoDock
4 (release 4.2.6) in the semi-flexible mode, with the Hco-Pgp-13_04 and
Hco-Pgp-13_52 PDB structures kept rigid, and prepared with AutoDock
Tools (Morris et al., 1998, 2009). The grid built by AutoGrid 4 included
95, 120, and 100 points in x, y, and z directions, with a grid spacing of
0.375 Å, to allow a good compromise between resolution of the ex-
plored volume and the size of the binding area (box dimensions
35.6×45.0×37.5 Å, centered in the inner cavity of Hco-Pgp-13 at the
point x= 23 Å; y= 78 Å; z= -2 Å). For each ligand conformer, 100
runs were performed using the Lamarckian genetic algorithm. All the
other parameters were set at the default value. The 100 generated poses
were assigned a score calculated by AutoDock that can be considered as
an estimated free energy of ligand binding (indicative of binding affi-
nity). They were then clustered as a function of the closeness of their
positions and conformations, with RMSD set at 2.0 Å, and finally ranked
by their binding score (determined for the best pose in the cluster). For
each lowest energy pose of selected clusters, the number and nature of
interacting residues were analyzed within the protein. Among these,
particular interest was given to residues belonging to the “hotspots for
drug binding”. These are a collection of 62 residues, as displayed in
Supplementary Table S3, coming from different experimental ap-
proaches that have been conducted for the purpose of determining the
key residues responsible for multidrug recognition by mammalian Pgp
(Hsa-ABCB1, Mmu-ABCB1a, Mmu-ABCB1b, Cgr-ABCB1) (Loo and
Clarke, 2001, 2002; Shilling et al., 2006; Loo et al., 2006a, 2006b; Aller
et al., 2009; Bessadok et al., 2011; Li et al., 2013). All these residues are
situated in the transmembrane part of the protein, and 14 of these 62
residues are common between at least two different approaches. Alto-
gether, they provide a frame in the inner chamber that offers a set of
anchor points for multi-specific recognition and binding, and eventual
translocation, of various transport ligands. Multiple protein sequence
alignments have been performed on Hco-Pgp-13, Cel-Pgp-1, human
ABCB1, murine ABCB1a and B1b, and Chinese hamster ABCB1, using
Muscle software (Edgar, 2004a), to identify the corresponding residues
in Hco-Pgp-13.
2.10. Immunohistochemistry on larvae and adult H. contortus cryosections
The anti-Hco-Pgp-13 antibodies validated in Western-blot were used
for immunohistofluorescence detection of Hco-Pgp-13 protein in L3
larvae and adult H. contortus. An anti-myosin antibody directed against
C. elegans myosin heavy chain A was also used to localize muscles
(product 5-6 of Developmental Studies Hybridoma Bank, University of
Iowa, IA, USA). Fresh worms were fixed in 4% PFA in PBS at 4 °C for
16 h. They were then washed and incubated in 30% sucrose in PBS at
4 °C for 16 h. Whole worms were individually embedded in an optimal
cutting temperature compound (OCT) (Thermo Fisher Scientific,
Waltham, MA, USA), they were quickly frozen to -80 °C and stored.
Cryosections were performed by slicing 20-30 μm thick transverse
sections with a Thermo Shandon cryotome (Thermo Fisher Scientific)
and slices were collected onto poly-L-lysine coated glass coverslips
(Sigma, USA), and kept at -80 °C before further processing.
Sections were incubated in Antibody Diluent (AbD) (PBS, 0.2%
gelatin fish skin, 0.1% sodium azide, 0.1% v/v Triton X-100) at 4 °C for
16 h, followed by incubation with the two primary antibodies: anti-
myosin and anti-Hco-Pgp-13 with 1/100 and 1/50 dilutions, respec-
tively, in AbD at 4 °C for 16 h. Five washes for 5min with AbD were
performed and the secondary fluorescent antibodies (Alexa Fluor 488-
labelled fragment of goat anti-rabbit IgG and Alexa Fluor 635 goat anti
-mouse IgG (Invitrogen, USA) were incubated at a 1/500 dilution at 4 °C
for 16 h. Sections were washed three times for 5min with AbD and then
PBS, mounted on slides using mounting medium (Sigma, Saint Louis,
Table 1
Percentage of amino acid identity and similarity of TMD1-TMD2 domains of various Pgps
relative to Cel-Pgp-1, as given by BlastP. The TMDs were extracted according to the
multiple sequence alignments generated by Muscle, as shown in Suppl. Fig. S2. For each
Pgp, TMD1 and TMD2 were determined by alignment with Cel-Pgp-1 TMDs as given by
the 4F4C crystal structure (Jin et al., 2012). TMD1 was considered as starting at TM1 of
4F4C, thus excluding the TMa-b transmembrane hairpin not described in other known
ABC transporter structures. Each TMD homology was calculated independently, and the
mean of the two values is reported. Bold: Cel-Pgps and Hco-Pgps showing a long N-
terminal sequence (>70 AAs). The list is displayed in decreasing order of similarity. ND:
not determined as Cel-Pgp-10 presents a longer TMD1 than other Pgps.
Cel-Pgp-1 % Identity % Similarity
Hco-Pgp-1 63 79
Hco-Pgp-9.1 50 69
Cel-Pgp-9 48 67
Hsa-Pgp 36 58
Cel-Pgp-2 35 57
Mmu-Abcb1a 35 56
Hco-Pgp-2 34 56
Hco-Pgp-13 33 54
Hco-Pgp-16 32 52
Cel-Pgp-3 30 52
Hco-Pgp-3 31 51
Cel-Pgp-4 30 51
Cel-Pgp-8 29 51
Cel-Pgp-12 28 51
Hco-Pgp-17 25 51
Cel-Pgp-5 30 50
Cel-Pgp-14 29 50
Cel-Pgp-13 27 50
Cel-Pgp-7 29 49
Cel-Pgp-6a 29 49
Hco-Pgp-11 25 46
Cel-Pgp-11 22 45
Hco-Pgp-10 22 42
Cel-Pgp-10 ND ND
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MO, USA) and observed under a fluorescent microscope. The most re-
presentative cross-sections were finally 3D analyzed under a confocal
microscope (Leica SP8 DMI6000, Wetzlar, Germany) at excitation and
emission wavelength of 488/520 nm, respectively for Alexa Fluor 488,
and 635/650 nm, respectively, for AlexaFluor 635.
3. Results
3.1. The Hco-Pgp-13 corrected cDNA sequence encodes a protein matching
the topology of an ABC transporter with high sequence similarity with Cel-
Pgp-12, Cel-Pgp-13 and Cel-Pgp-14
RNA was extracted from adult male and female H. contortus, reverse
transcribed into cDNA and amplified. Several primers (Supplementary
Table S1) were designed along the predicted sequence of Hco-Pgp-13
(ftp://ftp.sanger.ac.uk/pub/pathogens/Haemonchus/contortus) (Laing
et al., 2013). The full sequence obtained, named Hco-Pgp-13, corre-
sponds to a 3954 base pairs (bp) coding cDNA from the ATG start codon
to the TGA stop codon (Supplementary Figure S1) and is representative
of the transcript RNA present in the parasitic worms (GenBank No.
KX844966). Compared to the gene sequence previously published
(Laing et al., 2013), the alignment data revealed a deletion of 30 nu-
cleotides in the amplified cDNA sequence, which strictly matched a 30-
nucleotide repeat present in the Hco-Pgp-13 sequence predicted in the
published genome (Supplementary Figure S1). We deduced that this
was due to a misalignment of contigs in the genomic sequencing. In
addition, 90 single nucleotide polymorphisms (SNPs) were found over
the full length amplified cDNA, which represents 2.3% of the nucleotide
sequence (Supplementary Figure S1).
The deduced amino acid sequence of Hco-Pgp-13 contains 1317
residues, and corresponds to an expected molecular weight of
145.9 kDa. It contains eight N-glycosylation motifs, without putative O-
glycosylation sites or signal peptide (Fig. 1). It is predicted to possess
four structural domains with two hydrophobic transmembrane domains
(TMD) and two cytoplasmic domains. The predicted motifs in the nu-
cleotide binding domains (NBD) correspond to ABC transporter family
signature motifs (Hewitt and Lehner, 2003) LSGGQKQRI (residues
557–565) in NBD1, and LSGGQKQRI (residues 1215–1223) in NBD2.
Aromatic residues (Y427 and Y1085) were found located 25 amino
acids upstream of each Walker A motif. These conserved motifs, in-
volved in the hydrolysis of ATP, are consistent with a functional, pri-
mary active transporter.
A multiple sequence alignment was performed with all Hco-Pgps, all
Cel-Pgps and two mammalian Pgps: Hsa-Pgp and Mmu-ABCB1a, after
exclusion of the highly conserved NBDs (Supplementary Figure S2). A
phylogenetic tree (Fig. 2) shows that with and without NBDs, (Laing
et al., 2013), Hco-Pgp-13 displays a very high degree of homology to
Cel-Pgp-12, Cel-Pgp-13 and Cel-Pgp-14, which thus all three appear to
be orthologs of Hco-Pgp-13.
3.2. Tertiary structure of Hco-Pgp-13 was generated by homology modeling
to Cel-Pgp-1
Since Cel-Pgp-1 is the only crystallographic structure of a nematode
Pgp (Protein Data Bank: 4F4C), the homologies of Cel-Pgp-1 TMDs se-
quences with the TMDs sequences of all other aligned Pgps
(Supplementary Figure S2) were calculated using BlastP (Table 1). As
expected, Cel-Pgp-1 presented the highest homology for TMDs to Hco-
Pgp-1, with 63% identity and 79% similarity of residues, followed by
Cel-Pgp-9 and Hco-Pgp-9. Interestingly, N-terminal regions, in the
multiple alignment, showed a sequence which extends to 70-90 amino
acids for Hco-Pgp-10, Hco-Pgp-13, Cel-Pgp-1, Cel-Pgp-10, Cel-Pgp-11,
Cel-Pgp-12, Cel-Pgp-13 and Cel-Pgp-14, against 30-50 amino acids for
the nineteen other Pgp sequences aligned, including Hco-Pgp-1
(Table 1, bold, and Supplementary Figure S2). In the crystal structure of
Cel-Pgp-1, a transmembrane hairpin (TMa-b, Supplementary Figure S3)
was found in the N-terminal region (Jin et al., 2012). Among the Pgps
harboring this long N-terminal region (bold, Table 1), Hco-Pgp-13
TMDs showed the highest degree of homology to Cel-Pgp-1 TMDs, with
33% identity and 54% similarity. In contrast, the only other Pgp se-
quence of H. contortus harboring a long N-terminal region, Hco-Pgp-10,
only showed 22% identity and 42% similarity to Cel-Pgp-1 TMDs.
The Cel-Pgp-1 4F4C crystal structure was used as a template for
building 3D homology models of Hco-Pgp-13, according to the pairwise
alignment shown in Supplementary Figure S3. Two models, Hco-Pgp-
13_04 and Hco-Pgp-13_52, showed the highest accuracy and very si-
milar scores for quality evaluation (Supplementary Table S2). The open
inward-facing conformations of these two high quality models
(Supplementary Figure S4) were substantially superimposed. Closer
inspection of TMDs of both models showed transmembrane (TM) he-
lices aligned with Cel-Pgp-1 alpha helices, including the small hairpin
formed by the N-terminal regions, with a slight shift of their backbones.
The TM1 helix and the extracellular loop 1 (ECL1) were found to be
shorter in Hco-Pgp-13 than in Cel-Pgp-1 (Supplementary Figure S4B).
When comparing the two Hco-Pgp-13 models, a difference was
found in the middle of TM11, where the alpha helix is discontinued
only in Hco-Pgp-13_04. At the core of the TMDs, the orientation of the
side chains of residues varied between the two models from being al-
most superimposed (e.g., L366) to pointing in opposite directions (e.g.,
L1026) (Supplementary Figure S4C).
Interestingly, amino acids of these two Hco-Pgp-13 models, which
aligned with those experimentally found to interact with substrates in
mammalian Pgps (called “hotspot residues”) (Supplementary Table S3),
were mostly found (80%) to point towards the inner chamber formed
by the 12 TM helices, thus in an orientation favorable for interaction
with potential substrates.
3.3. Hco-Pgp-13 shows in silico high affinity binding sites for ACD and IVM
In order to obtain insights into the functioning of Hco-Pgp-13, we
studied, using in silico docking on the two structural models, the ability
of the protein to interact with two key ligands: ACD, a well-established
substrate of mammalian Pgp and Cel-Pgp-1, and IVM, which is the most
important anthelmintic used to control parasitic nematodes.
For ACD, the two lowest energy clusters obtained from the docking
calculations showed very good binding energies; -16.0 kcal/mol and
-14.4 kcal/mol for the Hco-Pgp-13_04 and Hco-Pgp-13_52 models, re-
spectively (Table 2); such energy scores are considered to indicate very
high affinity for ligand-protein interaction (Morris et al., 1998, 2009).
The binding location of ACD was very close in the two models, occu-
pying the inner chamber of Hco-Pgp-13 from its cytoplasmic opening to
its inner core (Fig. 3A and B). These two models of ACD binding showed
a similar number of interacting residues: 20 with Hco-Pgp-13_04 model
(including 11 hotspot residues) and 19 with Hco-Pgp-13_52 (including
9 hotspot residues). Twelve predicted interacting residues, among
which 7 hotspot residues, were common between the two models, with
some similarly oriented (e.g., E21, L365, T369) but most of them
pointing towards different orientations (e.g. Q108, M916, M995,
M1032, N1033) (Fig. 3C and D and Table 2). These differences would
explain the different lowest energy positions for ACD in the two models,
with different H-bonds formed. For example, Q108, which formed an H-
bond with Hco-Pgp-13_04 model, but not with Hco-Pgp-13_52, had a
very different orientation in the two models. In contrast, T369 formed
an H-bond with Hco-Pgp-13_52 but not with Hco-Pgp-13_04, despite
similar orientations. Two H-bonds were formed in both cases, and one
of them, formed with N1033, was common between the two models
(Fig. 3C and D and Table 2). All three H-bond forming residues were
hotspot residues, underlining their importance in substrate binding
across species. The role of the small hairpin formed by TMa-b was also
significant, as three residues from TMb, i.e. E21, K25 and L29, parti-
cipated in the stability of ACD on this site in both models (Fig. 3C and D
and Table 2). These results indicate a very high affinity of ACD for Hco-
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Pgp-13 with a very close binding site in the two models, located in the
cytoplasmic opening of the inner chamber, and thus not much depen-
dent on the orientation of partially flexible residues composing the
TMDs.
For IVM, the docking calculations, performed on each model of Hco-
Pgp-13, showed close lowest energy clusters, -11.2 kcal/mol and
-12.8 kcal/mol for the Hco-Pgp-13_04 model and the Hco-Pgp-13_52
model, respectively, indicating high affinity binding in both cases
(Table 2). The binding location of IVM on the Hco-Pgp-13_04 model
was close to the cytoplasmic opening of the chamber (Fig. 3A), whereas
the binding site of IVM on Hco-Pgp-13_52 was in the deepest part of the
inner chamber of the protein (Fig. 3B). These binding positions inter-
acted with 14 residues on model Hco-Pgp-13_04, and 21 residues on
model Hco-Pgp-13_52, including 4 hotspots and formed 2 H-bonds on
Hco-Pgp-13_04, and 14 hotspots and no H-bonds on Hco-Pgp-13_52
(Fig. 3E and F and Table 2). Thus the binding locations found on the
two models were different, with only 5 common residues and with
different H-bonds formed: S19 and E21 on Hco-Pgp-13_04, and V1029
and M1032 on Hco-Pgp-13_52 (Fig. 3E and F and Table 2). The binding
site of IVM on Hco-Pgp-13 thus appears dependent on the orientation of
amino-acids lining the binding chamber. For the Hco-Pgp-13_04 model,
it mostly superimposed with the binding site of ACD; the two molecules
sharing 9 common interacting residues, including 3 hotspots residues,
whereas on Hco-Pgp-13_52, the binding sites of IVM and ACD only
superimposed each other at their extremities; nonetheless sharing 6
interacting residues, including 4 hotspots residues.
From this analysis, it can be predicted that both ACD and IVM
specifically interact with Hco-Pgp-13 with high affinity at partially
overlapping locations within the inner chamber formed by the TMDs.
Consequently, these data predict competitive binding of these two li-
gands on Hco-Pgp-13.
3.4. Hco-Pgp-13 is functionally expressed in transfected P. pastoris cells
The ability of Hco-Pgp-13 to interact with ACD and IVM was also
studied by analyzing modulation of its ATPase activity. We transfected
P. pastoris cells with the pPICZ-Hco-Pgp-13-cmyc-his-tag vector. The
relative expression of Hco-Pgp-13 in the transfected cells was checked
by Western blot using an antibody anti-His tag and two specific anti-
bodies. To generate specific antibodies, two antigenic peptides were
designed to be specific to Hco-Pgp-13, compared to other H. contortus
Pgps. When proteins of crude membrane were analyzed by Western-
blot, only the 130-kDa protein, otherwise detected with an anti-His tag
antibody (Supplementary Figure S5A) reacted with each antibody,
showing that the two epitopes were antigenic (Supplementary Figure
S5B and C) and confirming that Hco-Pgp-13 was well expressed in the
membrane of the transfected P. pastoris. The anti-Hco-Pgp-13 anti-
bodies did not give any signal with untransfected mammalian LLCPK1
cells or untransfected P. pastoris cells, while the Hco-Pgp-13 transfected
cells gave a strong signal to the anti-Hco-Pgp-13 antibodies
(Supplementary Figure S5A, B, C). To confirm that the anti-Hco-Pgp-13
antibodies were specific, we checked for any cross reaction with Hco-
Pgp-2 and found no cross reactivity (Supplementary Figure S5D, E).
We found that P. pastoris membranes from cells expressing Hco-Pgp-
13 displayed a higher vanadate-sensitive ATPase activity
(150± 18 nmol/min/mg) compared to P. pastoris cells transfected with
pPICZ-HuMOR-cmyc-his-tag vector, used as control (95±5 nmol/min/
mg), showing that Hco-Pgp-13 displays a basal ATPase activity
(55±23 nmol/min/mg) in the absence of any exogenous compound.
3.5. Hco-Pgp-13 ATPase activity is modulated by ACD and IVM
ACD stimulated vanadate-sensitive ATPase activity in Hco-Pgp-13
expressing P. pastoris membranes, in a concentration dependent manner
with a biphasic profile (Fig. 4A). An activity enhancement of about 1.6-
fold and a half-activating concentration around 0.6–1 μM (EC50) were
Table 2
Docking characteristics and list of interacting residues of actinomycin D and
ivermectin in the Hco-Pgp-13 structure. The parameters and interacting residues listed in
column 1 stand for the lowest energy cluster of ACD on Hco-Pgp-13_04 (column 2) and Hco-
Pgp-13_52 (column 3), and of IVM on Hco-Pgp-13_04 (column 4) and Hco-Pgp-13_52 (column
5). X: contact residues; X: hotspot residues. H: residues establishing a hydrogen bond.
Legend for docking features: a) Number of poses: number of poses in the lowest energy
cluster of histogram of poses clustered at rmsd=2Å. b) Binding energy (kcal/mol): the energy
score calculated by Autodock 4.2. c) Interacting residues: number of contact residues as de-
termined by AutoDock Tools graphical interface. d) Hotspot residues: number of contact re-
sidues identified as hotspot residues according to our determination listed in Table S3. e)
Hydrogen bonds: number of H-bonds identified by AutoDock Tools between the docked ligands
and the protein receptor.
Molecule Actinomycin D Ivermectin
Hco-Pgp-13 model 04 52 04 52
Docking 
characteristics
Number of poses 21 42 19 17
Binding energy 
(kcal/mol) -16.0 -14.4 -11.2 -12.8
Interacting residues 20 19 14 21
Hotspot residues 11 9 5 14
Hydrogen bonds 2 2 2 2
Interacting residues
R11 X
S19 X H
S20 X
E21 X X H X
K25 X X
L29 X X
Q108 H X
S115 X
V118 X
L217 X
R220 X
F358 X
M362 X
L365 X X X X
L366 X
Y369 X H X
L373 X X
H377 X X X
L772 X
F776 X
L912 X X
A913 X
M916 X X X X
I917 X
L919 X X X
A920 X X
L921 X X
Q989 X
T992 X
M995 X X X
Y1000 X
F1018 X
L1025 X
L1026 X
S1028 H
V1029 X X X
V1031 X
M1032 X X X H
N1033 H H
S1035 X X
S1036 X
P1039 X
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observed. In contrast, IVM specifically inhibited the basal ATPase ac-
tivity of Hco-Pgp-13 with a concentration-dependent response curve
(Fig. 4B). The concentration giving 50% of the maximal inhibition
(IC50) was around 0.5–0.7 μM. In addition, we observed on Hco-Pgp-13
containing membranes, that the ACD-dependent ATPase stimulation
was completely inhibited in the presence of 5 μM of IVM (Fig. 4A).
In contrast, in membranes from P. pastoris control cells expressing
HuMOR, as well as in the membranes from non-transfected P. pastoris,
the activity was neither activated by ACD nor inhibited by IVM up to
10 μM (Fig. 4A and B). The slight inhibiting effect observed at 10-20 μM
is likely attributable to non-specific membrane perturbing effect, which
could also explain the small activity decrease observed at 20 μM ACD
on Hco-Pgp-13 containing membranes (Fig. 4A and B). Globally, these
ATPase modulations strongly indicate that ACD and IVM bind specifi-
cally to Hco-Pgp-13 with sub-micromolar apparent affinity.
Fig. 3. In silico binding of actinomycin D and
ivermectin to Hco-Pgp-13 model 04 (A, C, E)
and model 52 (B, D, F). A and B: Binding sites of
the 1st lowest energy clusters of ACD (ACD1)
(panel A) and IVM (IVM1) (panel B) on each
protein structure resulting from AutoDock 4 cal-
culations. The two molecules are represented to-
gether within each of the models of Hco-Pgp-13:
04 (A) and 52 (B). C-F: View of the interacting
residues of Hco-Pgp-13_04 (C and E) and Hco-
Pgp-13_52 (D and F) with ACD (C and D) or IVM
(E and F). Hco-Pgp-13_04 is represented in light
blue ribbon and Hco-Pgp-13_52 in grey ribbon.
ACD is represented in dark blue sticks (A and B)
or lines in atom type colour mode (C and D). IVM
is represented in red sticks (A and B) or lines in
atom type colour mode (E and F). Interacting
residues of both Hco-Pgp-13 models are re-
presented in sticks in atom type colour mode. All
images were generated using PyMol. (For inter-
pretation of the references to colour in this figure
legend, the reader is referred to the Web version
of this article.)
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3.6. Hco-Pgp-13 is expressed in H. contortus digestive, neuronal and
epithelial tissues
Given that Hco-Pgp-13 appears likely to be a functional transporter
that interacts with IVM and hence possibly plays a role in modulating
IVM levels in nematode tissues, it was of interest to determine the ex-
pression sites of Hco-Pgp-13. The two anti-Hco-Pgp-13 antibodies were
used as a mixture in immunofluorescence assays on transverse cryo-
sections of larvae and adult parasites. In larvae, the Hco-Pgp-13 ex-
pression was found in the seam cell between muscle quadrants and
more generally in the hypodermis around muscles, including dense
bodies between myosin filaments (grey and white arrows, Fig. 5A, pa-
nels I and II). Significant staining was also observed at epithelial cells
membranes of developing internal organs, corresponding to the gonad
or intestine, which could not be readily distinguished at this stage of
development (yellow arrow, Fig. 5A, panel II).
In the adult H. contortus, Hco-Pgp-13 signal was also found in seam
cells-excretory cells, between muscle quadrants and in the surrounding
hypodermis (grey and white arrows, Fig. 5B, panels I-IV), as well as at
the surface of the male gonad (yellow arrow, Fig. 5B, panel I). In adults,
some staining also appeared in the pharynx procorpus at the level of
pharyngeal nerve cords that contain cell bodies of epithelial cells,
longitudinal extensions of neurons and pharyngeal gland cell processes
(purple arrows, Fig. 5B panel II). The staining observed in the meta-
corpus and terminal bulb also matches the extensions or cell bodies of
pharyngeal neurons and gland cells (purple arrows, Fig. 5B, panels III
and IV). Additional staining appeared in the head sections between the
pharynx and seam cells (blue arrows, Fig. 5B panels III and IV), and
within the structure localized at the level of seam cells in other sections
(blue arrows, Fig. 5B, panel II). This corresponds to the location of
amphidial neurons. Indeed, their dendrites run parallel to the pharynx
from the nerve ring to the tip of the head, where seam cells end, and
correspond to the amphids. Overall, this broad protein localization
matches several organs of the digestive, neuronal, excretory and epi-
thelial systems, suggesting an important physiological role for Hco-Pgp-
13.
4. Discussion
There is evidence Pgp efflux pumps play a role in ML resistance in
nematodes. Since there is limited structural and functional information
on ABC transporters in parasitic nematodes, examining Pgps from H.
contortus, is important to understand their role. We focused on Hco-Pgp-
13 since its ortholog in C. elegans is expressed in the nematode amphids,
the strategic organs controlling chemotaxis, and for which a defect is
associated with IVM resistance (Urdaneta-Marquez et al., 2014; Menez
et al., 2016). Our overall objective was to characterize Hco-Pgp-13 and
determine whether it could interact with drugs in order to predict its
capacity to transport anthelmintics. Our data strongly support that Hco-
Pgp-13 specifically interacts with IVM with high affinity, and may thus
actively transport IVM and protect sensitive nematode tissues.
4.1. Topology and 3D structural models of Hco-Pgp-13
We first corrected the predicted Hco-pgp-13 cDNA from the H. con-
tortus genome (Laing et al., 2013) by identifying a misalignment of
contigs due to a 30-nucleotide repeat in the previously published
genomic sequence, absent in the full-length amplified cDNA. In addi-
tion, 90 single nucleotide polymorphisms (SNPs) were found in the
amplified cDNA, similar to the 2.3% frequency of SNPs reported in
different H. contortus populations. Based on the corrected sequence
(GenBank No. KX844966), the full-length cDNA allowed prediction of a
protein containing 1137 amino acids (MW 146 kDa), with typical do-
main arrangement of full-size ABC proteins, including 2 TMDs, and 2
NBDs containing the ABC transporter family consensus motifs, con-
sistent with a primary active transporter. Hco-Pgp-13 shared close
similarities with Cel-Pgp-12, Cel-Pgp-13 and Cel-Pgp-14, suggesting
these proteins are orthologs between the two nematode species, pos-
sibly sharing some functional homologies.
Since the TMDs of Hco-Pgp-13 also share high sequence homology
with the TMDs of Cel-Pgp-1 (54% similarity by BlastP), we generated
3D structures of Hco-Pgp-13 by homology modeling using the Cel-Pgp-1
crystal structure 4F4C (Jin et al., 2012), as template. Two model pro-
teins Hco-Pgp-13_04 and Hco-Pgp-13_52 were selected according to
their similarly high quality scores for several parameters (Table S2).
They were both organized into two halves containing each six TM he-
lices, but they presented an unusual supplementary transmembrane
hairpin TMa-b at the N-terminus. For both models, 80% of hotspots
residues, involved in drug binding in mammalian Pgps (Table S3), were
detected and pointed towards the inner chamber lined by the TMDs.
Nineteen percent of them were conserved, in terms of their nature,
slightly below the 26% of hotspots residues conserved in Cel-Pgp-1
(David et al., 2016) as compared with mammalian Pgps. These data
suggest that the overall protein topology of the inner chamber of Hco-
Pgp-13 is consistent with a multispecific drug recognition site compa-
tible with a multidrug transport function. However, only a small
number of ABC proteins are endowed with a multidrug recognition
capacity, and this raises the question of ligands interacting with Hco-
Pgp-13.
4.2. High-affinity interaction of Hco-Pgp-13 with ACD and IVM
To study the ability of two toxins, ACD and IVM, to bind to Hco-Pgp-
13, we characterized the putative binding sites in silico, by docking the
two drugs on the two homology models described above. Allowing
AutoDock 4 to “challenge” two different protein conformations with a
semi-flexible docking strategy gave it the opportunity to explore a
larger conformational space of the protein, which could simulate, to
some extent, a flexible docking calculation strategy. The two con-
formations may reflect a preexisting equilibrium of two pools of pro-
teins which may be stabilized upon ligand binding as the result of the
movement of interacting residues or various membrane domains (Pike,
2004; Andre et al., 2008). ACD was chosen because this drug has been
reported to strongly stimulate the ATPase activity of Cel-Pgp-1 (Jin
et al., 2012) and to interact with the Cel-Pgp-1 binding pocket in silico,
having the highest affinity among all tested ligands (David et al., 2016).
We found that ACD and IVM both bound with high affinity in the inner
chamber, revealing they are ligands of Hco-Pgp-13. The large ligand
ACD (1255 Da) bound in the chamber from the cytoplasmic opening to
the transmembrane inner core of the protein, whatever the protein
model, while IVM (875 Da) presented a dual binding site, depending on
the conformation of the protein. One of the binding sites of IVM sub-
stantially overlapped that of ACD in one protein model (_04), whereas it
was deeper in the inner chamber and only partially overlapped the
binding site of ACD in the other protein conformation (_52). The data
revealed that the affinity of the binding site for a given ligand may
depend on the conformation of the protein. Each ligand is expected to
stabilize the lower energy conformation state of the formed complex.
ACD seems to bind preferentially to the Hco-Pgp-13_04 conformation,
whereas IVM has a higher affinity for the Hco-Pgp-13_52 conformation.
In other words, the two built structural models are not “alternative”
models, but are complementary conformations describing a preexisting
dynamic transconformation equilibrium contributing to the specific
affinity recognition of different ligands. The docking approach also
provided important insights into drug interacting residues of the Hco-
Pgp-13 binding pocket. Several residues formed H-bonds, among them,
E21, L365, M1032 are common for ACD and IVM binding. In addition,
several amino acids also aligned to hotspot residues on mammalian
Pgp, suggesting that the inner chamber of Hco-Pgp-13 could form a
binding domain competent for recognizing transport substrates of un-
related chemicals.
The ability to bind ACD and IVM was confirmed in vitro by
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measuring modulation of ATPase activity in cell membranes expressing
Hco-Pgp-13. ACD specifically stimulated the basal Hco-Pgp-13 ATPase
activity. The ACD half-activating concentration for Hco-Pgp-13 stimu-
lation (EC50= 0.6–1 μM) was higher than that for Cel-Pgp-1
(EC50≈ 0.05 μM) (Jin et al., 2012); however, the experimental condi-
tions differed between the two sets of measurements. The in silico
docking of ACD on Cel-Pgp-1 showed that it interacts with a compar-
able binding energy as with Hco-Pgp-13, at a similar site located at the
cytosolic opening of the inner chamber (David et al. to be submitted).
Since ATP hydrolysis is required to drive active translocation across cell
membranes, our data indicate that ACD is transported by Hco-Pgp-13
similarly to Cel-Pgp-1. Interestingly, in the absence of any added drug, a
higher ATPase activity in the membranes of yeast expressing Hco-Pgp-
13, as compared to that of the control membranes, suggests that Hco-
Pgp-13 can transport some substrates present in the membranes.
IVM inhibited the basal Hco-Pgp-13 ATPase activity in a con-
centration dependent-manner with an apparent half-maximal in-
hibitory concentration of 0.5–0.7 μM, which suggests that it can spe-
cifically bind to Hco-Pgp-13. In addition, the total inhibition of the
ACD-stimulated ATPase activity by 5 μM IVM is consistent with binding
to the same site as that inhibiting the basal activity, which was half-
saturated at ≈ 0.6 μM. The consistency between the two effects of IVM
strongly supports that it binds to a specific site on Hco-Pgp-13 with a
sub-micromolar affinity. It is noteworthy that it has also been reported
that the interaction of IVM with mammalian Pgp induces an inhibition
of its basal ATPase activity (Lespine et al., 2007). This inhibition was
explained as the consequence of a slower translocation of IVM than that
of endogenous substrates, including cholesterol (Garrigues et al., 2002).
In silico docking calculations indicated a lower affinity for IVM than
ACD for its specific binding site (binding energy of -12,8 vs -16,0 kcal/
mol, respectively). In contrast, in vitro experiments showed similar
apparent affinities, in the 0.5 to 1 μM range. If we consider that Hco-
Pgp-13 behaves like mammalian Pgp and, in its open inward-facing
conformation, binds its hydrophobic substrates from within the mem-
brane (Sharom, 2008; Eckford and Sharom, 2009), the in vitromeasured
affinity of an amphiphilic/hydrophobic ligand will be a combination of
its membrane partition coefficient and the “theoretical affinity” with its
specific binding site. Since IVM is much more hydrophobic than ACD, it
will be more concentrated within the membrane, hence the in silico data
can be quantitatively reconciled by considering that the higher mem-
brane partition coefficient of IVM compensates for its lower theoretical
affinity. In silico calculations also showed that IVM was docked, for the
more stable conformation, in the deepest part of the inner chamber of
the protein, which was in agreement with the previously determined in
silico docking of IVM on Cel-Pgp-1 (David et al., 2016). Finally the in
silico data predict that IVM should inhibit ACD-induced ATPase sti-
mulation, due to the partial overlap of their drug binding sites, and this
was observed in vitro.
4.3. Tissue immunolocalization of Hco-Pgp-13
It was of interest to determine in which tissues of H. contortus Hco-
Pgp-13 is expressed. Hco-Pgp-13 was found in the digestive apparatus,
which can be an entry route for xenobiotics; in the seam cells lining the
excretory canals, involved in xenobiotic elimination; and in head neu-
rons, possibly the amphids, which may play a role in the access of ML to
the targets responsible for lethal anthelmintic effects on nematodes.
Since shortening of amphidial dentrites is associated with resistance to
IVM in H. contortus and in C. elegans (Freeman et al., 2003; Urdaneta-
Marquez et al., 2014; Menez et al., 2016), the staining of adult head
neurons matching the amphids suggests a link for Hco-Pgp-13 in-
volvement in IVM resistance. The pharyngeal structures were also
stained, and may correspond with the neurons innervating the pharynx.
Since a major effect of ML on nematodes is paralysis of the pharyngeal
Fig. 4. Modulation of the ATPase activity of Hco-Pgp-13 by ac-
tinomycin D and ivermectin. Vanadate-sensitive ATPase activity
was measured on freshly prepared membranes from either un-
transfected P. pastoris (wildtype (WT); black cross), or P. pastoris
transfected with pPICZ-HuMOR-cmyc-his-tag vector (HuMOR; black
circles) or with pPICZ-Hco-Pgp-13-cmyc-his-tag vector (Hco-Pgp-13;
white circles), at 37 °C, as a function of ACD concentration in the
absence (white and black symbols) or presence (grey circles) of 5 μM
IVM (A) or IVM concentration (B). In Panel A, the vanadate-sensi-
tive activity, measured as described in Material and Methods, was
normalized to the control activity determined without drug for the
same strain. The data are the mean±SD of triplicates made on two
or three independent experiments carried out on HuMOR, Hco-Pgp-
13 and WT membranes, respectively. The lines are fits using
GraphPad PRISM.
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muscles, Hco-Pgp-13 expression in pharyngeal neurons might protect
worms from IVM effects. The expression of Hco-Pgp-13 in the epithelial
cells of the larvae and adult gonad resembled previous finding of Hco-
Pgp-9.1 expression in the uterus (Godoy et al., 2016), and an involve-
ment in reducing toxic compounds reaching embryos, as was shown in
C. elegans (Brinke et al., 2013) and mammalian placental tissue
(Nakamura et al., 1997; Kolwankar et al., 2005).
The Hco-Pgp-13 expression matches the global transcript localiza-
tion of all of its closest ortholog genes in C. elegans with Cel-Pgp-12
expressed in the excretory cell, Cel-Pgp-13 in the posterior intestine and
amphids of adults, Cel-Pgp-14 in the anterior region and first bulb of the
pharynx in the adults and larvae, and Cel-Pgp-15 in the adult head and
tail neurons, and in the embryo (Zhao et al., 2004). Interestingly, the
three genes Cel-Pgp-12, Cel-Pgp-13, Cel-Pgp-14, together with the pseu-
dogene Cel-Pgp-15, form a cluster of tandemly duplicated genes on
chromosome X of C. elegans (Zhao et al., 2004). Since, H. contortus lacks
the Pgp-12 and Pgp-14 proteins, the broad localization observed here
for Hco-Pgp-13 may cover all the functions ensured in C. elegans by its
three ortholog Pgps.
This study represents the first structural and functional analysis of a
parasitic nematode Pgp, describing its molecular interaction with two
important drugs, ACD and IVM. This provides critical information on
the protective function of Hco-Pgp-13 against toxicity of IVM and other
drugs. Its location, mainly in strategic tissues of H. contortus, underlines
the importance of this transporter and its possible role in anthelmintic
resistance.
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Fig. 5. Immunolocalization of Hco-Pgp-13 in Haemonchus contortus L3 larvae (A) and adult (B). A. Left panel: differential interference contrast (DIC) image and DAPI signal
superimposed; right panel: myosin and Hco-Pgp-13 staining superimposed. I and II: Different Z-stacks of one slice in the mid-body observed after incubation of primary and secondary
antibodies. III: Slice in the mid-body observed with no primary antibody incubation. All slices were incubated with DAPI, and numerous nuclei are observed in the gonad and intestine in
development and not well distinguishable. sh= supplementary sheath of the L3 stage larvae, ct= cuticle, al= alae, in= intestine, go= gonad, mu=muscle. White arrow: hypodermis,
grey arrow: seam cell, yellow arrow: epithelial cells of the gonad or intestine. Scale bar= 2 μm. B. Left panel: DIC image; middle panel, myosin staining; right panel, Hco-Pgp-13 staining.
I: Slice in the mid-body of a male parasite. II: Slice in the anterior region of the pharynx (procorpus). III: Section in the mid-region of the pharynx (metacorpus). IV: Section in the
posterior region of the pharynx (terminal bulb). IeIV: Incubation of primary and secondary antibodies. V: No primary antibody incubation. ct= cuticle, ph=pharynx, go= gonad,
in= intestine. White arrow: hypodermis, grey arrow: seam cell-excretory cell, blue arrow: neuronal structures, purple arrow: pharyngeal glands, yellow arrow: gonad. Scale bar=20 μm.
(For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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